ConductScience.org, home

Gene · 22925

PLA2R1: phospholipase A2 receptor 1

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. PLA2R1: phospholipase A2 receptor 1. Genes, record 22925. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/22925

On this page

Gene

Symbol
PLA2R1
HGNC
Name
phospholipase A2 receptor 1
HGNC
NCBI Gene ID
22925
NCBI Gene
HGNC ID
HGNC:9042
HGNC
Ensembl
ENSG00000153246
NCBI Gene
Aliases
CLEC13C, PLA2-R, PLA2G1R, PLA2IR, PLA2R
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q13018Secretory phospholipase A2 receptor1,4632Ensembl, GeneID, HGNC

Source UniProt

Patents67

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026527559 A2026-08-1414Q13018Espacenet
JP 2026526573 A2026-08-0714Q13018Espacenet
EP 4753742 A22026-06-1014Q13018Espacenet
EP 4754146 A12026-06-1014Q13018Espacenet
JP 2026004568 A2026-01-1457879Q13018Espacenet
JP 2025541179 A2025-12-1827Q13018Espacenet
EP 4650780 A22025-11-193197Q13018Espacenet
EP 4641201 A22025-10-292763Q13018Espacenet
EP 4630459 A12025-10-1527Q13018Espacenet
JP 2025147176 A2025-10-0610476Q13018Espacenet

1 to 10 of 67

See all 67 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants591

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitlePLA2R1 papersNewest fiscal year
K24AI130263Immunopathology of Indirect Airway Hyperresponsiveness in Asthma32025
P30CA008748Cancer Center Support Grant32025
P30CA015083Mayo Clinic Comprehensive Cancer Center Support Grant32025
P30CA016672Cancer Center Support Grant32025
R01DK076690Complement-mediated injury of the kidney: New mechanisms and novel therapies32025
R01DK105124Genetics of IgA nephropathy by integrative network-based association studies32025
U01DK100876The Columbia PCC for CureGN: the Cure Glomerulonephropathy network32025
ZIACL090034Mechanisms of Pain and Immune Processes32025
ZIADE000704Clinical and Mechanistic Investigations of Salivary Gland Dysfunction32025
P20GM113226Hepatobiology and Toxicology COBRE22025

1 to 10 of 591Source NIH's project files

See all 591 nih grants

Papers2,349

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
LAMA5 pathogenic variant uncovers a novel autoantigen in membranous nephropathy.Genes Dis202742763546PubTator, text miningPubMed
Diagnostic pitfall: NSAID-induced membranous nephropathy with PLA2R positivity, IgG1-predominant deposits, C1q positivity, and concurrent acute interstitial nephritis-A case report.Clin Chim Acta202742503368PubTator, text miningPubMed
Rituximab Outcomes and Predictors of Treatment Failure in Primary Membranous Nephropathy: A Retrospective Cohort Study.J Clin Med202642795840PubTator, text miningPubMed
The role of serum BAFF, CFB, MCP-1 and anti-PLA2R antibodies in the efficacy evaluation of patients with membranous nephropathy.J Med Biochem202642781234PubTator, text miningPubMed
Risk prediction of PLA2R-Ab-negative membranous nephropathy: an interpretable multicenter machine learning model.Front Immunol202642746065PubTator, text miningPubMed
Anti-PLA2R autoantibodies induce complement activation via IgG subclass-dependent epitope pairings in membranous nephropathy.J Clin Invest202642709482PubTator, text miningPubMed
From immune dysregulation to renal injury: mechanistic insights and translational opportunities in immune-mediated nephropathies.Front Cell Dev Biol202642707564PubTator, text miningPubMed
Histopathological predictors of renal outcomes in idiopathic membranous nephropathy with a focus on global sclerotic glomeruli ratio.Sci Rep202642706286PubTator, text miningPubMed
An unusual presentation of membranous nephropathy with primary and secondary features: a case report.BMC Nephrol202642687155PubTator, text miningPubMed
Comparison of efficacy and safety among four therapeutic regimens in primary membranous nephropathy with high anti-PLA2R antibody titers: a single-center retrospective cohort study.BMC Nephrol202642687143PubTator, text miningPubMed

1 to 10 of 2,349

See all 2,349 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/22925

GET https://conductscience.org/api/genes/v1/22925/patents?page=2